Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monika Brüggemann

Showing results (1-10 of 142) with videos related to

Pageof 15
Sort By:
Hematology. American Society of Hematology. Education Program|December 10, 2017
Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretationMonika Brüggemann, Michaela Kotrova
Blood Advances|January 4, 2018
Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretationMonika Brüggemann, Michaela Kotrova
Seminars in Oncology|February 1, 2012
Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principleMonika Brüggemann, Nicola Gökbuget, Michael Kneba
Blood|October 4, 2012
Has MRD monitoring superseded other prognostic factors in adult ALL?Monika Brüggemann, Thorsten Raff, Michael Kneba
Molecular Diagnosis & Therapy|April 29, 2017
Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?Michaela Kotrova, Jan Trka, Michael Kneba, et al.
Acta Haematologica|June 5, 2004
Significance of minimal residual disease in lymphoid malignanciesMonika Brüggemann, Christiane Pott, Matthias Ritgen, et al.
Methods in Molecular Biology (Clifton, N.J.)|November 9, 2020
Next-Generation Sequencing Technology to Identify Minimal Residual Disease in Lymphoid MalignanciesMichaela Kotrova, Nikos Darzentas, Christiane Pott, et al.
Cancers|December 10, 2021
The Serine Protease CD26/DPP4 in Non-Transformed and Malignant T CellsGuranda Chitadze, Ulrike Wehkamp, Ottmar Janssen, et al.
Plos Computational Biology|February 12, 2021
The impact of phenotypic heterogeneity of tumour cells on treatment and relapse dynamicsMichael Raatz, Saumil Shah, Guranda Chitadze, et al.
Methods in Molecular Biology (Clifton, N.J.)|May 27, 2022
cfDNA-Based NGS IG Analysis in LymphomaChristiane Pott, Michaela Kotrova, Nikos Darzentas, et al.
Pageof 15

Showing results (1-10 of 142) with videos related to

Sort By:
Pageof 15
Hematology. American Society of Hematology. Education Program|December 10, 2017
Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretationMonika Brüggemann, Michaela Kotrova
Blood Advances|January 4, 2018
Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretationMonika Brüggemann, Michaela Kotrova
Seminars in Oncology|February 1, 2012
Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principleMonika Brüggemann, Nicola Gökbuget, Michael Kneba
Blood|October 4, 2012
Has MRD monitoring superseded other prognostic factors in adult ALL?Monika Brüggemann, Thorsten Raff, Michael Kneba
Molecular Diagnosis & Therapy|April 29, 2017
Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?Michaela Kotrova, Jan Trka, Michael Kneba, et al.
Acta Haematologica|June 5, 2004
Significance of minimal residual disease in lymphoid malignanciesMonika Brüggemann, Christiane Pott, Matthias Ritgen, et al.
Methods in Molecular Biology (Clifton, N.J.)|November 9, 2020
Next-Generation Sequencing Technology to Identify Minimal Residual Disease in Lymphoid MalignanciesMichaela Kotrova, Nikos Darzentas, Christiane Pott, et al.
Cancers|December 10, 2021
The Serine Protease CD26/DPP4 in Non-Transformed and Malignant T CellsGuranda Chitadze, Ulrike Wehkamp, Ottmar Janssen, et al.
Plos Computational Biology|February 12, 2021
The impact of phenotypic heterogeneity of tumour cells on treatment and relapse dynamicsMichael Raatz, Saumil Shah, Guranda Chitadze, et al.
Methods in Molecular Biology (Clifton, N.J.)|May 27, 2022
cfDNA-Based NGS IG Analysis in LymphomaChristiane Pott, Michaela Kotrova, Nikos Darzentas, et al.
Pageof 15